These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Oral physostigmine in Alzheimer's disease. Davis KL; Mohs RC; Davis BM; Horvath TB; Greenwald BS; Rosen WG; Levy MI; Johns CA Psychopharmacol Bull; 1983; 19(3):451-3. PubMed ID: 6635123 [No Abstract] [Full Text] [Related]
43. Continuous physostigmine infusion in rats with excitotoxic lesions of the nucleus basalis magnocellularis: effects on performance in the water maze task and cortical cholinergic markers. Mandel RJ; Chen AD; Connor DJ; Thal LJ J Pharmacol Exp Ther; 1989 Nov; 251(2):612-9. PubMed ID: 2810114 [TBL] [Abstract][Full Text] [Related]
44. Potential pharmacotherapy of Alzheimer disease. A comparison of various forms of physostigmine administration. Becker R; Giacobini E; Elble R; McIlhany M; Sherman K Acta Neurol Scand Suppl; 1988; 116():19-32. PubMed ID: 3043998 [TBL] [Abstract][Full Text] [Related]